Cargando…
From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities
PURPOSE OF REVIEW: In this review, we highlight the most important cellular and molecular mechanisms that contribute to cardiac inflammation and fibrosis. We also discuss the interplay between inflammation and fibrosis in various precursors of heart failure (HF) and how such mechanisms can contribut...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527069/ https://www.ncbi.nlm.nih.gov/pubmed/28707261 http://dx.doi.org/10.1007/s11897-017-0343-y |
_version_ | 1783252910931443712 |
---|---|
author | Suthahar, Navin Meijers, Wouter C. Silljé, Herman H.W. de Boer, Rudolf A. |
author_facet | Suthahar, Navin Meijers, Wouter C. Silljé, Herman H.W. de Boer, Rudolf A. |
author_sort | Suthahar, Navin |
collection | PubMed |
description | PURPOSE OF REVIEW: In this review, we highlight the most important cellular and molecular mechanisms that contribute to cardiac inflammation and fibrosis. We also discuss the interplay between inflammation and fibrosis in various precursors of heart failure (HF) and how such mechanisms can contribute to myocardial tissue remodelling and development of HF. RECENT FINDINGS: Recently, many research articles attempt to elucidate different aspects of the interplay between inflammation and fibrosis. Cardiac inflammation and fibrosis are major pathophysiological mechanisms operating in the failing heart, regardless of HF aetiology. Currently, novel therapeutic options are available or are being developed to treat HF and these are discussed in this review. SUMMARY: A progressive disease needs an aggressive management; however, existing therapies against HF are insufficient. There is a dynamic interplay between inflammation and fibrosis in various precursors of HF such as myocardial infarction (MI), myocarditis and hypertension, and also in HF itself. There is an urgent need to identify novel therapeutic targets and develop advanced therapeutic strategies to combat the syndrome of HF. Understanding and describing the elements of the inflammatory and fibrotic pathways are essential, and specific drugs that target these pathways need to be evaluated. |
format | Online Article Text |
id | pubmed-5527069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-55270692017-08-08 From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities Suthahar, Navin Meijers, Wouter C. Silljé, Herman H.W. de Boer, Rudolf A. Curr Heart Fail Rep Comorbidities of Heart Failure (C Angermann & F Edelmann, Section Editors) PURPOSE OF REVIEW: In this review, we highlight the most important cellular and molecular mechanisms that contribute to cardiac inflammation and fibrosis. We also discuss the interplay between inflammation and fibrosis in various precursors of heart failure (HF) and how such mechanisms can contribute to myocardial tissue remodelling and development of HF. RECENT FINDINGS: Recently, many research articles attempt to elucidate different aspects of the interplay between inflammation and fibrosis. Cardiac inflammation and fibrosis are major pathophysiological mechanisms operating in the failing heart, regardless of HF aetiology. Currently, novel therapeutic options are available or are being developed to treat HF and these are discussed in this review. SUMMARY: A progressive disease needs an aggressive management; however, existing therapies against HF are insufficient. There is a dynamic interplay between inflammation and fibrosis in various precursors of HF such as myocardial infarction (MI), myocarditis and hypertension, and also in HF itself. There is an urgent need to identify novel therapeutic targets and develop advanced therapeutic strategies to combat the syndrome of HF. Understanding and describing the elements of the inflammatory and fibrotic pathways are essential, and specific drugs that target these pathways need to be evaluated. Springer US 2017-07-13 2017 /pmc/articles/PMC5527069/ /pubmed/28707261 http://dx.doi.org/10.1007/s11897-017-0343-y Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Comorbidities of Heart Failure (C Angermann & F Edelmann, Section Editors) Suthahar, Navin Meijers, Wouter C. Silljé, Herman H.W. de Boer, Rudolf A. From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities |
title | From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities |
title_full | From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities |
title_fullStr | From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities |
title_full_unstemmed | From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities |
title_short | From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities |
title_sort | from inflammation to fibrosis—molecular and cellular mechanisms of myocardial tissue remodelling and perspectives on differential treatment opportunities |
topic | Comorbidities of Heart Failure (C Angermann & F Edelmann, Section Editors) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527069/ https://www.ncbi.nlm.nih.gov/pubmed/28707261 http://dx.doi.org/10.1007/s11897-017-0343-y |
work_keys_str_mv | AT suthaharnavin frominflammationtofibrosismolecularandcellularmechanismsofmyocardialtissueremodellingandperspectivesondifferentialtreatmentopportunities AT meijerswouterc frominflammationtofibrosismolecularandcellularmechanismsofmyocardialtissueremodellingandperspectivesondifferentialtreatmentopportunities AT silljehermanhw frominflammationtofibrosismolecularandcellularmechanismsofmyocardialtissueremodellingandperspectivesondifferentialtreatmentopportunities AT deboerrudolfa frominflammationtofibrosismolecularandcellularmechanismsofmyocardialtissueremodellingandperspectivesondifferentialtreatmentopportunities |